The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
《每日生物技术脉搏》：布里斯托尔·迈尔斯、BridgeBio 签署肿瘤学协议、FDA 点头支持Lava Therapeutics血液癌研究等
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是过去 24 小时内生物技术领域的主要进展摘要：
Stocks In Focus
焦点股票
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio与Bristol Myers签署了肿瘤学SHP2抑制剂的许可协议
BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398 in oncology.
布里奇生物制药公司（纳斯达克股票代码：BBIO）宣布了独家许可布里斯托尔迈尔斯施贵宝公司纽约证券交易所代码：BMY）将在肿瘤学领域开发和商业化 BBP-398。
BridgeBio will receive an upfront payment of $90 million, up to $815 million in milestone payments and tiered royalties in the low- to mid-teens.
BridgeBio将获得9000万美元的预付款、高达8.15亿美元的里程碑付款和低到中期的分级特许权使用费。
BridgeBio will retain the option to acquire higher royalties in the U.S. in connection with funding a portion of development costs upon the...
BridgeBio将保留在美国获得更高特许权使用...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。